Galapagos Reports Topline Data From Two Trials With GLPG3667 in Dermatomyositis, Systemic Lupus Erythematosus

MT Newswires Live05:49

Galapagos (GLPG) said Thursday that GLPG3667 reached the primary endpoint in a dermatomyositis trial.

GLPG3667 showed a "statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity" compared with placebo, the company said.

Meanwhile, in a systemic lupus erythematosus trial, GLPG3667 demonstrated "numerical improvements on several secondary endpoints" compared with placebo, but it did not reach "statistical significance in primary endpoint analysis," Galapagos said.

Galapagos said Gilead (GILD) has agreed to temporarily waive some rights under a 10-year option, licensing and collaboration deal between the companies, allowing Galapagos to seek external partnership opportunities for GLPG3667.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment